Valuation: AnaptysBio, Inc.

Market Cap 1.63B 1.41B 1.32B 1.21B 2.29B 155B 2.31B 15.49B 6.08B 77.66B 6.13B 6B 257B P/E 2026 *
-223x
P/E 2027 * 13.9x
Enterprise Value 1.54B 1.33B 1.24B 1.14B 2.16B 146B 2.18B 14.61B 5.73B 73.27B 5.78B 5.66B 243B EV / Sales 2026 *
16.3x
EV / Sales 2027 * 8.74x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.25%
1 week+5.47%
Current month+3.05%
1 month-11.75%
3 months-20.63%
6 months+14.80%
Current year+13.43%
1 week 51.85
Extreme 51.85
56.65
1 month 49.71
Extreme 49.71
70.91
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
2/11/26 Fiscal year

Chief Financial Officer

30,000 0.1083%
1/15/26 Fiscal year

Director

33,000 0.1192%
1/7/26 Fiscal year

Chief Executive Officer

67,957 0.2454%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%+5.47%+132.12%+197.89% 1.63B
+4.35%+19.90%+60.59%+95.21% 62.53B
+2.83%-3.03%+27.40%+67.25% 52.43B
+0.91%-0.83%-17.01%-6.42% 23.1B
+0.27%-3.98%-11.28%+352.77% 21.4B
+0.40%+5.29%+30.11%-9.63% 21.17B
+0.75%-0.84%+33.80%-25.25% 17.76B
+9.88%+19.73%+229.67%+385.49% 15.47B
+2.08%-3.28%+21.67%+564.59% 14.68B
+1.25%+2.48%+51.36%+180.00% 14.08B
Average +2.25%+3.87%+55.84%+180.19% 24.43B
Weighted average by Cap. +2.74%+4.60%+43.55%+136.49%

Financials

2026 *2027 *
Net sales 94.28M 81.65M 76.12M 70.01M 132M 8.96B 134M 894M 351M 4.49B 354M 346M 14.86B 153M 133M 124M 114M 215M 14.57B 217M 1.45B 570M 7.29B 575M 563M 24.14B
Net income -7.47M -6.47M -6.03M -5.55M -10.47M -710M -10.59M -70.85M -27.81M -355M -28.05M -27.43M -1.18B 129M 111M 104M 95.58M 180M 12.24B 182M 1.22B 479M 6.12B 483M 473M 20.28B
Net Debt -92.22M -79.88M -74.46M -68.48M -129M -8.77B -131M -875M -343M -4.39B -346M -339M -14.53B -293M -254M -237M -218M -411M -27.86B -415M -2.78B -1.09B -13.94B -1.1B -1.08B -46.18B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-08-05 US$54.99 -0.25% 307,059
26-08-04 US$55.13 +2.74% 417,554
26-08-03 US$53.66 +0.56% 433,730
26-07-31 US$53.36 -3.05% 451,375
26-07-30 US$55.04 +5.56% 1,069,578
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
55.13USD
Average target price
87.09USD
Spread / Average Target
+57.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock